|Bid||8.35 x 4000|
|Ask||8.40 x 4000|
|Day's range||8.33 - 8.58|
|52-week range||5.81 - 22.13|
|Beta (5Y monthly)||0.65|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
It seems like a long time ago that Inovio Pharmaceuticals (NASDAQ: INO) was considered a leader in the race to develop an effective coronavirus vaccine. Unsurprisingly, investors mostly gave up on Inovio, and its shares have lost more than half their value in the past 12 months. Inovio hasn't given up on its COVID-19 vaccine program, but the biotech can't conduct a phase 3 clinical trial for INO-4800 in the U.S. at the moment.
Rather, the buzz has been about the retail movement and the desire to seek out the next short squeeze. In simple terms, short-sellers are investors betting on a lower share price. Since a company's share price can't go below $0, gains are capped at 100% for pessimists.
Despite the stock market hitting seemingly one new high after another since the year began, Wall Street still sees value in equities. Based on the highest Wall Street price target for each of the following small-cap stocks, implied upside ranging from 158% to as much as 329% may await. The first tiny tot that Wall Street appears to be really excited about is clinical-stage biotech stock Vaxart (NASDAQ: VXRT).